Converging opinions of a multidisciplinary group of French experts on diagnostic and therapeutic modalities for Alzheimer type dementia;Convergences d'un groupe pluridisciplinaire d'experts francais sur les modalites du diagnostic et des therapeutiques de la maladie d'Alzheimer au stade dementiel

Revue Neurologique

Volumn 156, Issue 5, 2000, Pages 542-552

  Petit, H ^a   Albarede J L ^a   Bakchine, S ^a   Boulliat, J ^a   Cogneau, J ^a   Darcourt, G ^a   Dubois, B ^a   Forette, F ^a   Franco, A ^a   Heres J ^a   Hinault, P ^a   Laurent, B ^a   Leger J M ^a   Marin La, R Meslée ^a   Montagne, B ^a   Poncet, M ^a   Robert, P ^a   Sorbe G ^a   Touchon, J ^a   Velas, B ^a   Vetel, J M ^a   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; DIAGNOSTIC APPROACH ROUTE; FRANCE; NOTE; PRACTICE GUIDELINE; TREATMENT PLANNING;

AGED; ALZHEIMER DISEASE; DIAGNOSIS, DIFFERENTIAL; DISABILITY EVALUATION; FRANCE; HUMANS; NOOTROPIC AGENTS; PATIENT CARE TEAM;

EID: 0342313575     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (78)

1. e édition (Version internationale, Washington). Traduction française par J.-D. Guelfi et al., 1 056 pages, Masson, Paris.
2. BARBERGER-GATEAU P, COMMENCES D, GAGNON M, LETENNEUR L, SAUVEL C, DARTIGUES J.F. (1992). Instrumental activities of daily living as a screening tool for cognitive impairments and dementia in elderly community dwellers. J Am Geriatr Soc, 40: 1129-1134.
3. BARBERGER-GATEAU P, DARTIGUES JF, LETENNEUR L. (1993). Four instrumental activities of daily living score as a predictor of one-year incident dementia. Age and Ageing, 22: 457-463.
4. BENOIT M, DYGAI I, MIGNECO O, ROBERT P et al. (1999). Behavioral and psychological symptoms in Alzheimer's disease. Dement. Geriatr Cogn Disord, 10: 511-517.
5. BLACKER D, TANZI RE. (1998). The genetics of Alzheimer disease. Arch Neurol, 55: 294-296.
6. BREITNER JCS. (1996). The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med, 47: 401-411.
7. BRENNER DE, KUKULL W, STERGACHIS A et al. (1994). Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease. A population-based case-control study. Am J Epidemiol, 140: 262-267.
8. BRODATY H, CLARK J, BANGULI M. et al. (1998). Screening for cognitive impairment in general practice: toward a consensus. Alzheimer Dis Assoc Disord, 12(1): 1-13.
9. BURNS A, JACOBY R, LEWY R. (1990). Psychiatric phenomena of Alzheimer's disease III: Disorders of Mood. Br J Psychiatry, 157: 81-86.
10. th Congress of the European Federation of Neurological Societies; Lisbon, Portugal; September 7-11.
11. COSTA PT, WILLIAMS TF, SOMERFIELD M. et al. (1996). Recognition and initial assessment of Alzheimer's disease and related dementias. Rockville, Md: US dept of health and human services, public health agency, agency for health care policy and research. AHCPR publication 97-0702.
12. COTRELL V, WILD K. (1999). Longitudinal study of self imposed driving restrictions and deficit awareness in patients with Alzheimer's disease. Alzheimer's disease and associated disorders, 13, 3: 151-156.
13. e édition, pp 443, Springer-Verlagg, New York.
14. DARTIGUES JF, GAGNON M, MICHEL P et al. (1991). The PAQUID research program on the epidemiology of dementia: methods and initial results. Rev Neurol (Paris), 147: 225-230.
15. DONALDSON C, BURNS A. (1999). Burden of Alzheimer's disease: helping the patient and caregiver. Journ of Geriatric Psychiatric and Neurology, 12: 21-28.
16. DRACHMAN DA, SWEARER J.M. (1993). Driving and Alzheimer's disease: the risk of crashes. Neurology, 43: 2448-2456.
17. DRICKAMER MA, LACHS MS. (1992). Should patients with Alzheimer's disease be told their diagnosis? N Engl J Med, 326: 947-951.
18. EBLY EM, HOGAN DB, PARHAD IM. (1995). Cognitive impairment in the non-demented elderly. Arch Neurol, 52: 612-619.
19. EVANS DA, FUKENSTEIN HH, ALBERT MS et al. (1989). Prevalence of Alzheimer's disease in a community population of older persons is higher than previously reported. JAMA, 262: 2551-2556.
20. FEIG DS. - Prevention of osteoporotic fractures in women by estrogen replacement therapy (1994). In Goldbloom RB, The Canadian guide to clinical preventive bealth care, pp 621-631. Canada Communication Group, Ottawa.
21. FISHER P, SIMANYI M, DANIELCZYK W. (1990). Depression in dementia of the Alzheimer type and in multi-infarct dementia. Am J Psychiatry, 147: 1484-1487.
22. FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR. (1975). "Mini-Mental State"; a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12: 189-198.
23. FORETTE F et al. (1998). Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst Euro) trial. Lancet, 352: 1344-1351.
24. Forums Alzheimer de Régions (décembre 1998). Maladie d'Alzheimer au stade léger à modéré. Livre blanc des Forums Alzheimer.
25. Forums Alzheimer de Régions (mars 1999). Maladie d'Alzheimer au stade sévère. Livre blanc des Forums Alzheimer.
26. GILLESPIE ND, MARION ET et al. (1999). A survey of attitudes and knowledge of geriatricians to driving in elderly patients. Age and Ageing, 28: 53-57.
27. HEEREN TJ, LAGAAY AM, HUMANS W, ROOYMANS HG. (1991). Prevalence of dementia in the "oldest old" of a Dutch community. J Am Geriatr Soc, 35: 755-759.
28. HENDRIE HC, OSUNTOKUN BO, HALL KS et al. (1995). Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry, 152: 1485-1492.
29. th Congress of the European Federation of Neurological Societies; Lisbon, Portugal; September 7-11.
30. HOFMAN A, ROCCA WA, BRAYNE C et al. (1991). The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. EURODEM Prevalence Research Group. Int J Epidemiol, 20: 736-748.
31. JORM AF, CHRISTENSEN H, HENDERSON AS et al. (1996). Informant ratings of cognitive decline of elderly people: relationship to longitudinal change on cognitive tests. Age and Ageing, 25 (2): 125-129.
32. Journal Officiel No 98 ; 27 avril 1999 ; p 6256.
33. KAFONEK S, ETTINGER WH, ROCA R et al. (1989). Instruments for screening for depression and dementia in a long-term care facility. J Am Geriatr Soc, 37: 29-34.
34. KATZ IR, JESTE DV, MINTZER JE et al. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry, 60; 2: 107-115.
35. KAUFER DI, CUMMINGS JL, CHRISTINE D. (1996). Effects of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol, 9: 1-6.
36. KERTESZ A, DAVIDSON W, Fox H. (1997). Frontal lobe behavioural inventory: Diagnostic criteria for frontal lobe dementia. Can J Neurol Sci, 24: 29-36.
37. KNAPP MJ, KNOPMAN DS, SALOMON PR et al. (1994). A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease: the Tacrine Study Group. JAMA, 271: 985-991.
38. KNOPMAN D, SCHNEIDER LS, DAVIS K et al. (1996). Long-term tacrine (Cognex) treatment effects on nursing home placement and mortality: the Tacrine Study Group. Neurology, 47: 166-177.
39. KUKULL WA, SCHELLENBERG GD, BOWEN JD (1996). Apolipoprotein E in Alzheimer's disease risk and case detection. A case-control study. J Clin Epidemiol, 49: 1143-1148.
40. LARSON EB, EDWARDS JK, O'MEARA E et al. (1996). Neuropathologic diagnosis outcomes from a cohort of outpatients with suspected dementia. J Gerontol, 51: M313-M318.
41. LAWTON MP, BRODY EM. (1969). Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist, 9: 179-186.
42. Le traitement de la démence (1999). Conclusions de la Conférence canadienne de consensus sur la démence. JAMC, 160 (Suppl. 12).
43. Les personnes dépendantes en institution. (Août 1999). INSEE Première, no 669.
44. LEYS D, PASQUIER F. (1999). Hypertension artérielle et déclin cognitif. Rev Neurol, 155, 9: 743-748.
45. MAYEUX R, SAUNDERS AM, SHEA S et al. (1998). Utility of the Apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med, 338: 506-511.
46. MCKEITH IB, GALASKO D, KOSALA K. (1996). Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology, 47: 1113-1124.
47. MEGA MS, CUMMINGS JL, FIORELLO T et al. (1996). The spectrum of behavorial changes in Alzheimer's disease. Neurology, 46: 130-135.
48. MINTZER JE, HOERNIN KS et al. (1998). Treatment of agitation in patients with dementia. Clinics in Geriatric Medicine, 14, 1: 147-174.
49. MITTELMAN MS, FERRIS SH, SHULMAN E, STEINBERG G, LEVIN B. (1996). A family intervention to delay nursing home placement of patients with Alzheimer's disease. A randomized controlled trial. JAMA, 276: 1725-1731.
50. NYTH AL, GOTTFRIES CG, LYBY K et al. (1992). A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concommitant dementia. Acta Psychiatr Scand, 86: 138-145.
51. PASQUIER F, HÉNON H, LEYS D. (1999). Facteurs de risques et mécanismes des démences post-AVC. Rev Neurol, 155, 9: 749-753.
52. PATTERSON C. (1994). Screening for cognitive impairment. In Goldbloom RB, The Canadian guide to clinical preventive health care, pp. 902-911. Canada Communications Group, Ottawa.
53. PATTERSON MB, BOLGER J.P. (1994). Assessment of behavioral symptoms on Alzheimer disease. Alzheimer Dis Assoc Disord, 8 (Suppl. 3): 4-20.
54. PETIT H, BAKCHINE S, DUBOIS B et al. (1998). Convergences d'un groupe pluridisciplinaire d'experts français sur les modalités du diagnostic et du traitement médicamenteux de la maladie d'Alzheimer au stade démentiel. Rev Geriatr, 23: 6.
55. PETIT H, BAKCHINE S, DUBOIS B et al. (1998). Convergences d'un groupe pluridisciplinaire d'experts français sur les modalités du diagnostic et du traitement médicamenteux de la maladie d'Alzheimer au stade démentiel. Rev Neurol (Paris), 154; 5: 432-438.
56. POITRENAUD J, KALAFAT M, HUGONOT-DIENER L, PIETTE F, DEROUESNE C. (1998). GRECO: «Standardisation et étalonnage français du MMS ». Journées de Neurologie de langue française, Paris.
57. POST SG, WHITEHOUSE PJ, BINSTOCK RH et al. (1997). Consensus Statement: the clinical introduction of genetic testing for Alzheimer disease. JAMA, 277: 832-836.
58. RADA RT, KELLNER R. (1976). Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc, 24: 105-107.
59. RASMUSSON DX, BRANDT J, STEELE C et al. (1996). Accuracy of clinical diagnosis of Alzheimer's disease and clinical features of patients with non-Alzheimer neuropathology. Alzheimer Dis Assoc Discord, 10: 180-188.
60. ROBERT P et al. (1998). Maladie d'Alzheimer, Collection Année Gérontologique, 5: 63-67.
61. ROCKWOOD K, EBLY E, HACHINSKI V, HOGAN D. (1994). Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol, 54: 33-39.
62. ROCKWOOD K, PARHAD I, HACHINSKI V et al. (1994). Diagnosis of vascular dementia: Consortium of Canadian Centres for Clinical Cognitive Research Consensus Statement. Can J Neurol Sci, 1994; 21: 358-364.
63. ROGERS SL, FARLOW MR, DOODY RS et al. and the Donepezil Study Group. - A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 50: 136-145.
64. ROGERS SL, FRIEDHOFF LT, APTER JT et al. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease-results of a US multicentre, randomized, double-blind; placebo-controlled trial. Dementia, 7: 293-303.
65. RÖSLER M, ANAND R et al. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ, 318: 633-638.
66. SCHNEIDER LS, POLLOCK VE, LYNESS SA. (1990). A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc, 28: 553-563.
67. SCHULZ R, O'BRIEN AT, BOOKWALA J, FLEISSNER K. (1995). Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist, 35: 771-791.
68. e édition, pp 531-540, Williams & Wilkins, Baltimore.
69. SMALL GW, RABINS PV, BARRY PP et al. (1997). Diagnosis and treatment of Alzheimer disease and related disorders. Consensus of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA, 278: 1363-1371.
70. STERN Y, ALPERT M, BRANDT J et al. (1994). Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission and death in Alzheimer's disease prospective analysis from the predictors study. Neurology, 44: 2300-2307.
71. TILVIS RS, STRANDBERG TE, JUVA K. (1998). Apolipoprotein E phenotypes, dementia and mortality in a prospective population sample. J Am Geriatr Soc, 46: 712-715.
72. TOMBAUGHT TN, MCINTYRE NJ. (1992). The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc, 40: 922-935.
73. TOUCHON J, PORTET-TARADO F, RITCHIE K. (1998). Troubles psycho-comportementaux de la maladie d'Alzheimer. Rev Prat, 48 : 1898-1905.
74. US Dept of Veterans Affairs, University Health-System Consortium (1997). Dementia Identification and Assessment: Guidelines for Primary Care Practitioners. Oak Brook, Ill: University Health-System Consortium.
75. VAN DUIJN CM, CLAYTON D, CHANDRA V. (1991). Familial aggregation of Alzheimer's disease and related disorders. A collaborative re-analysis of case-control studies. Int J Epidemiol, 20: S13-20.
76. WITTHAUS E, OTT A et al. (1999). Burden of mortality and morbidity from dementia. Alzheimer Disease and Associated Disorders, 13, 3: 176-181.
77. WRAGG RE, JESTE DV. (1989). Overview of depression in Alzheimer's disease. Am J Psychiatry; 145: 577-587.
78. ZARIT SH, REEVER KE, BACH-PETERSON J. (1980). Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist, 20: 649-655.